Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD109 in Obstructive Sleep Apnea (LunAIRo)
NCT05811247Phase 3Completed
- Sponsor
- Apnimed, Inc.
- Start
- Aug 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aroxybutynin and atomoxetine in obstructive sleep apnea (OSA) (2 arms), sponsored by Apnimed, Inc. Primary endpoint: Apnea-Hypopnea Index at 6 months. Started Aug 2023; status: completed.
02
Drugs
aroxybutyninatomoxetine
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT05811247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05811247.